Natural and engineered kallikrein inhibitors: an emerging pharmacopoeia.
about
Mastering the canonical loop of serine protease inhibitors: enhancing potency by optimising the internal hydrogen bond networkProteolytic activation of prochemerin by kallikrein 7 breaks an ionic linkage and results in C-terminal rearrangement.Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs).Natural and engineered plasmin inhibitors: applications and design strategies.Proteomic and other analyses to determine the functional consequences of deregulated kallikrein-related peptidase (KLK) expression in prostate and ovarian cancer.Targeting kallikrein-related peptidases in prostate cancer.Cystine-knot peptides: emerging tools for cancer imaging and therapy.Unleashing the therapeutic potential of human kallikrein-related serine proteases.Kallikrein-related peptidases targeted therapies in prostate cancer: perspectives and challenges.Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies.KLK-targeted Therapies for Prostate Cancer.Inhibitors of kallikrein-related peptidases: An overview.A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineeringMechanism-based selection of a potent kallikrein-related peptidase 7 inhibitor from a versatile library based on the sunflower trypsin inhibitor SFTI-1Comparing Pathways of Bradykinin Formation in Whole Blood From Healthy Volunteers and Patients With Hereditary Angioedema Due to C1 Inhibitor Deficiency
P2860
Q28740672-B30AC6E3-7C2C-4DE2-BEF5-4EA3569B693CQ34333142-E7DF2CC2-079D-4733-8ECA-226965F19D79Q34457491-FA47E73A-F2DD-464D-98F5-A5D2AEEF6634Q37975189-C102B280-6234-4A96-8F2B-674810829D0DQ38188878-6C9DCFE3-98C4-4036-8515-372409E3D6F4Q38191293-9C7CEDB5-D08E-41FC-BE7B-36141D1CB319Q38243927-7071680E-B00B-4950-9240-00459C27C02DQ38362486-ADE6E699-535F-4B1F-AD25-AAC535A22717Q38413737-15D8C630-CF10-45E4-A4A6-B1922EAF32D0Q38760061-569A61D3-63DD-4E91-8A0A-5CADE07AC7D5Q38967486-77A1989B-9E33-45E9-98C2-B8253D9D1757Q39369735-B3E038E9-F7ED-4C83-BCBB-2F5E9B1143B5Q56888917-A0849CC9-F594-4DB6-811B-121092518159Q58022615-A1568E1E-54E5-42D0-8878-C98278E41529Q58586459-FC0C8A13-70D5-419B-8BB6-E54AA335D234
P2860
Natural and engineered kallikrein inhibitors: an emerging pharmacopoeia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Natural and engineered kallikrein inhibitors: an emerging pharmacopoeia.
@en
Natural and engineered kallikrein inhibitors: an emerging pharmacopoeia.
@nl
type
label
Natural and engineered kallikrein inhibitors: an emerging pharmacopoeia.
@en
Natural and engineered kallikrein inhibitors: an emerging pharmacopoeia.
@nl
prefLabel
Natural and engineered kallikrein inhibitors: an emerging pharmacopoeia.
@en
Natural and engineered kallikrein inhibitors: an emerging pharmacopoeia.
@nl
P2093
P2860
P356
P1433
P1476
Natural and engineered kallikrein inhibitors: an emerging pharmacopoeia.
@en
P2093
Joakim E Swedberg
Jonathan M Harris
Simon J de Veer
P2860
P304
P356
10.1515/BC.2010.037
P577
2010-04-01T00:00:00Z